Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO …
2 days ago · LLY. Eli Lilly (NYSE: LLY) stock is up a mammoth 770% in five years. It is trading at new all-time highs in 2024 thanks to the incredible success and popularity of its diabetes and weight loss ...
All News | Eli Lilly and Company
Lilly's latest press releases, stories, news resources and more.
Lilly.com | Eli Lilly and Company
Aug 20, 2024 · INDIANAPOLIS , July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Next-generation drug from Eli Lilly boosts weight loss to 24% ... - CNN
Jun 26, 2023 · Eli Lilly’s Mounjaro, cleared for type 2 diabetes and awaiting FDA approval for weight loss, targets both GLP-1 and a hormone called GIP, and has produced weight loss of 21 to 23%.
Lilly releases Zepbound® (tirzepatide) single-dose vials, …
5 days ago · Distributed through LillyDirect ® 's self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesity. INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an …
News Release - Eli Lilly and Company
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. PDF Version. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
Eli Lilly and Company (LLY) Latest Stock News & Headlines
Get the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.
Lilly to Acquire Versanis to Improve Patient Outcomes in ...
Jul 14, 2023 · INDIANAPOLIS and NEW YORK, July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.
Lilly hits record high after Mounjaro fuels forecast raise, rival data
Aug 8, 2023 · Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
Eli Lilly expects FDA decision on Alzheimer’s treatment ... - CNBC
Jul 17, 2023 · Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.
Skip to content